

Date:12<sup>th</sup>April, 2022

: 1

To,
The Secretary,
BOMBAY STOCK EXCHANGE LIMITED,
1st Floor, New Trading Ring
Rotunda Building, P.J.Towers,
Dalal Street,
Mumbai-400001.

Scrip Code:524564

Dear Sir,

Sub: Intimation under Regulations 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding outcome of Board Meeting

In compliance with Regulation 33 & 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Audited Financial Results for the Fourth Quarter and Financial Year ended 31<sup>st</sup>March 2022 which have been reviewed by the Audit Committee and approved by the Board at their meetings held today i.e., 12<sup>th</sup>April 2022 and also the Audit Report furnished by the Statutory Auditors of the Company. We are also forwarding herewith the press release being issued in this connection.

The meeting of the Board of Directors of the Company commenced at 10.30AM and concluded at 12.10 PM

We would request you to please take note of the same.

Thanking you sir,

For GAYATRI BIOORGANICS LIMITED

T.V.Sandeep Kumar Reddy

Chairman



Off: +91-40-6661 7089
Mobile: 98480 18791

98491 35573 95421 87777

Auditor's Report on Quarterly Financial Results and Year to Date Results of M/s. Gayatri Bioorganics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
M/s. Gayatri Bioorganics Limited.

We have audited the quarterly financial results of M/s. Gayatri Bioorganics Limited for the quarter ended 31.03.2022 and the year-to-date results for the period 01.04.2021 to 31.03.2022, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under;, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31.03.2022 as well as the year-to-date results for the period from 01.04.2021 to 31.03.2022.

For N G Rao & Associates

Chartered Accountants

FRN: 009399S

(G. Nageswara Rao)

Partner

MembershipNo.207300

Place: Hyderabad Date: 12.04.2022

UDIN: 22207300 AGWCCI5824



## STATEMENT OF AUDITED FINANCIALS RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

(₹ in Lakhs unless otherwise stated)

		Quarter Ended			Year ended	
_	Particulars	March 31, 2022	December 31,	March 31, 2021	March 31, 2022	March 31, 2021
Sr.	Farticulars	,	2021			(4 124 1)
		(Refer Note 3)	Unaudited	(Refer Note 3)	(Audited)	(Audited)
	C. d. L. Occupations					
	Continuing Operations Revenue from operations (Refer Note 5)	-	-	-	-	-
	Other Income	-	-		-	-
2 3	Total Revenue from operations (1+2)			-	-	-
3						
4	Expenses (Refer Note 5)	7.38	7.25	7.12	29.09	28.48
	Employee Benefits Expenses	7.36	0.02	0.07	0.03	0.10
	Finance Cost	_	0.02			-
	Depreciation and Amortisation Expenses	6.36	3.04	7.55	20.49	21.15
	Other Expenses (Including Excise expense)	13.74	10.31	14.75	49.61	49.74
	Total Expenses			(11.75)	(40.61)	(49.74)
5	Profit/(Loss) before exceptional and extraordinary items and tax (3-4)	(13.74)	(10.31)	(14.75)	(49.61)	(49.74)
6	Add/(Less): Exceptional Items	-	-	(1456)	(49.61)	(49.74)
7	Profit / (loss) before tax for the period / year (5-6)	(13.74)	(10.31)	(14.75)	(49.01)	(42.74)
8	Tax Expense	-	(10.21)	(14.75)	(49.61)	(49.74)
9	Profit/(Loss) from continuing operations for the period / year (7-8)	(13.74)	(10.31)	(14.75)	(47.01)	(1211.)
			(10.21)	(14.75)	(49.61)	(49.74)
13	Net Profit/(Loss) for the period / year (9+12)	(13.74)	(10.31)	(14.75)	(45.01)	(1311.1)
14	Other Comprehensive Income (net of Tax) Items that will not be reclassified to Statement of Profit and Loss					
	(a) Remeasurement of employee benefit obligation	Y			-	-
	(a) Remeasurement of employee benefit dongardon (b) Income tax relating to above item	-	-	-	•	· -
1.0	Total Comprehensive Income/(Loss) for the period / year (After tax) (13+14)				(40.61	(49.74)
15	Total Comprehensive incomer(E033) for the period of the	(13.74)	(10.31)	(14.75)	(49.61)	(49.74)
		7,878.81	7,878.81	7,878.81	7,878.81	7,878.81
16	Paid-up Equity Share Capital	7,878.81	7,070.01	,,	(11,176.70	(11,126.96)
17	Other Equity					
18	Earnings per share in ₹ for discontinued operations (annualised except for					
10	quarter)		(0.01	(0.02)	(0.06	(0.06)
	Basic	(0.02)		/		/
	Diluted	(0.02)	(0.01	/ (0.02)	(0.00	1
	(see accompanying notes to the financial results)					



F +91 40 6610 0333



## NOTES

- The above financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meeting held on Apr 12, 2022.
- The above financial results are extracted from the Audited Financial Statements of the Company, which are prepared in accordance with Indian Accounting Standards ('Ind AS') as prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder.
- 3 The figures for the quarter ended March 31, 2022 and March 31, 2021 are balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended December 31, 2021 and December 31, 2020 respectively.
- 4 The financial statements have been prepared on a going concern basis based upon Comfort letter given by the promoters of the Company for any other business to be continued by them in the future.
- 5 The Company doesn't have more than one segment. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- The figures for the corresponding previous period have been regrouped/reclassified/restated wherever necessary to make them comparable with the current year's classification.

By order of the Board

For Gayatri Bioorganics Limited

T. Sandeep Kumar Reddy

Chairman DIN: 00005573

Place: Hyderabad Date: April 12, 2022



STATEMENT OF ASSETS AND LIABILITIES (₹ in Lakhs unless otherwise stated)

Sr. No.	Particulars	As at March 31 2022 (Audited)	As at March 31 2021 (Audited)
I.	ASSETS		
1	Non-Current Assets		
	(a) Financial assets		
	(i) Investments	0.15	0.15
	(ii) Other Financial Assets	9.06	9.06
		9.21	9.21
2	Current Assets	1),	9
	(a) Financial Assets		
	(i) Trade Receivables	48.46	48.46
	(ii) Cash and Cash equivalents	3.29	43.76
	(iii) Other Financial Assets	11.97	11.97
	(b) Other Current assets	150.62	145.97
		214.34	250.15
	TOTAL ASSETS	223.55	259.36
-	EQUITIES AND LIABILITIES		
	i i		
1	EQUITY	7,878.81	7,878.81
	(a) Equity Share Capital	(11,226.31)	
	(b) Other Equity	(3,347.50)	
	N N A PARK MERCAL CO		
1	LIABILITIES Non-Current Liabilities		
2	Brigging Colors (1975)		
	(a) Financial Liabilities	170.16	170.16
	(i) Borrowings	170.16	170.16
3	Current Liabilities		
	(a) Financial Liabilities	1	
	(i) Borrowings	3,340.35	3,340.35
	(ii) Trade Payables	46.94	44.19
	(b) Other Current liabilities	13.60	2.54
	(-)	3,400.89	3,387.08
	TOTAL EQUITY AND LIABILITIES	223.55	259.36



Regd. & Corp. Office:

 $\textbf{Gayatri Bio } \textbf{O} \textbf{rganics Limited,} \ \textbf{B1,} \ \textbf{1st Floor,} \ \textbf{6-3-1090,} \ \textbf{TSR Towers,}$ 

Raj Bhavan Road, Somajiguda, Hyderabad 500 082. Telangana

CIN NO: L24110TG1991PLC013512

T +91 40 6610 0111 / 6610 0222 F +91 40 6610 0333

E info@gayatribioorganics.com gayatribioorganics@gmail.com www.gayatribioorganics.com



Gayatri BioOrganics Limited
Cash Flow Statement for the year ended on March 31, 2022

(₹ in lakhs unless otherwise stated)

	(₹ in lakhs unles	(₹ in lakhs unless otherwise stated)			
Particulars	For the year ended March 31, 2022	For the year ended March 31, 2021			
A. Cash Flow from Operating Activities		and the contract of the contra			
(Loss) before tax	(49.61)	(49.73)			
Adjustments for:					
- Finance Costs	0.03	0.10			
Operating Profit Before Working Capital Changes	(49.58)	(49.63)			
Changes in operating assets and liabilities:					
(Increase) / Decrease in Operating Assets:					
- Non-current Financial Assets & Other Assets	-	(0.18)			
- Other current assets	(4.65)	(1.66)			
Increase / (Decrease) in Operating Liabilities:					
- Trade Payables	2.73	(0.39)			
- Other Current Liabilities	11.06	0.12			
Cash (used in) / generated from Operations	(40.44)	(51.73)			
- Direct Taxes paid	-				
Net cash (used in) Operating Activities (A)	(40.44)	(51.73)			
B. Cash Flow from Investing Activities					
- Interest Received	-	-			
Net cash flow (used in) investing activities (B)	-				
C. Cash Flow from Financing Activities		_			
- Interest and Finance Charges paid	(0.03)	(0.10)			
Net cash flow from financing activities (C)	(0.03)	.(0.10)			
Net increase / (decrease) in cash and cash equivalents (A + B + C)	(40.47)	(51.83)			
Cash and Cash Equivalents at the beginning of year	43.76	95.60			
Cash and Cash Equivalents at the end of year (Refer Note - 2.3(b) & 2.5)	3.29	43.76			
5					
		The second secon			

The notes referred to above form an integral part of the financial statements





1

To,
The Secretary,
BOMBAY STOCK EXCHANGE LIMITED,
1st Floor, New Trading Ring
Rotunda Building, P.J.Towers,
Dalal Street,
Mumbai-400001.

Scrip Code:524564

Sub: Declaration pursuant to Regulation 33(3) (d) of the Securities & Exchange Board of India (Listing Obligation and Disclosure Requirements) (Amendment) Regulations, 2015 ["LODR"]

Ref: SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016

In compliance with Regulation 33(3) (d) of LODR as amended by the SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016 we hereby declare that, Statutory Auditors of our Company M/s. N.G. RAO & ASSOCIATES., Chartered Accountants (FRN: 009399S) have issued an Audit Report with unmodified opinion on Audited Standalone Financial Results of the Company for the quarter and year ended 31st March, 2022.

You are requested to take the same on record & oblige.

Yours Sincerely,

For GAYATRI BIOORGANICS UMITED

ACHANTA PRABHAKAR RAO y derab Chief Financial Officer







Registered office: B3, Third floor, 6-3-1090, TSR Towers, Raj Bhavan Road, Somajiguda, Hyderabad - 500 082  $\,$  G / Website: www.gayatribioorganics.com, CIN: L24110TG1991PLC013512

Extract of Audited Financial Results for the Year ended March 31, 2022

(₹ In Lakhs)

PARTICULARS	Quarter Ended		Year Ended	
	31-03-2022	31.03.2021	31-03-2022	31-03-2021
Total income from operations (net)	-	-	-	-
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(13.74)	(14.75)	(49.61)	(49.74)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(13.74)	(14.75)	(49.61)	(49.74)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(13.74)	(14.75)	(49.61)	(49.74)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(13.74)	(14.75)	(49.61)	(49.74)
Equity Share Capital	7,878.81	7,878.81	7,878.81	7,878.81
Earning Per Share (of Rs. 10/- each) (for continuing and discontinued operations) - - Basic and Diluted	(0.02)	(0.02)	(0.06)	(0.06)

## Note:

1. The above is an extract of the detailed format of the Quarterly Financial Results for the Quarter ended March 31, 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Unaudited financials Prepared. The full format of the said quarterly Financial Results is available on the Stock Exchange websites. (www.bseindia.com) and on Company's website: www.gayatribioorganics.com.

Hyderabad

Date: April 12, 2022